Outcomes of remission induction therapy for ANCA-associated vasculitis in the elderly.
Faten AqeelLillian XuAntonio SalasYumeng WenShaker M EidDuvuru GeethaPublished in: Clinical rheumatology (2023)
CYC, CYC + RTX, and RTX are equally effective for remission induction in elderly patients with ANCA-GN. Induction therapy with RTX only was associated with a lower risk of leukopenia compared to CYC-containing regimens. Infections requiring hospitalization were similar among all groups. End-stage kidney disease at one year was comparable among the 3 groups. Key Points • Cyclophosphamide, Rituximab, and Cyclophosphamide+Rituximab are equally effective in remission induction in elderly patients with ANCA glomerulonephritis. • The use of Rituximab only was associated with a lower risk of bone marrow suppression compared to Cyclophosphamide only. • More information is needed on the comparative safety of induction therapy strategies in elderly ANCA glomerulonephritis patients.
Keyphrases
- middle aged
- bone marrow
- diffuse large b cell lymphoma
- high dose
- community dwelling
- low dose
- ejection fraction
- newly diagnosed
- end stage renal disease
- hodgkin lymphoma
- chronic lymphocytic leukemia
- healthcare
- stem cells
- mesenchymal stem cells
- type diabetes
- rheumatoid arthritis
- ulcerative colitis
- systemic lupus erythematosus
- patient reported outcomes
- health information